Table 2 Literature overview for published articles addressing NMUS and chemotherapy/immunotherapy induced polyneuropathy (publications included until March 2023)
References | Publication/study type | No. of pat | Type of cancer | Treatment regimen | Control | Ultrasound findings |
|---|---|---|---|---|---|---|
Portland et al. [26] | Case report | 1 | Breast cancer | Paclitaxel | No | NMUS performed of both median nerves only |
Enlargement of median nerve CSA at the wrists and palms, bilaterally | ||||||
Hypoechogenic nerves | ||||||
Reduced mobility of nerves | ||||||
Erdmann et al. [27] | Monocentric, retrospective study | 27* | n.a | Platinum based regimen | 19 pat. with CIP + 20 pat. with CIDP | No CSA analysis described, focused on echogenicity only |
No significant difference described (tendency to slightly hyperechogenic findings) | ||||||
Lycan et al. [28] | Monocentric, prospective cross-sectional study | 20 | Breast cancer | Taxane | healthy historical controls | decreased sural nerve size increased median nerve size, but on compression site only |
Alberti et al. [29] | Review | n.a | n.a | n.a | n.a | n.a |
Pitarokoili et al. [30] | Monocentric, prospective study | 13 | mPC | oxaliplatine, irinotecan and 5-fluorouracil (FOLFIRI-NOX) | No | Tendency for CSA increase at compression sites for ulnar nerve (elbow) and radial nerve (radial groove) increased CSA for fibular nerve (at fibular head; 10/13) and the tibial nerve (at knee and ankle) |
Briani et al. [31] | Monocentric, prospective study | 15 | CRC | Oxaliplatine | No | CSA increase of median and ulnar nerves at compression sites (9/15), in 4/15 pat. bilaterally |